Notices Notices
The Task Force on Intractable and Rare Diseases of the Industrial Policy Committee of the Japan Pharmaceutical Manufacturers Association (JPMA) has released " Proposals on Intractable and Rare D iseases" to help solve the problems of patients with intractable and rare diseases and their families.
Based on the recommendations, the Task Force held active discussions with stakeholders from various fields, including patient groups, pharmaceutical companies, government, medical institutions, and academia, with the aim of realizing the recommendations by creating an environment where patients and their families can easily access necessary information, promoting understanding of rare diseases in society, and promoting the development of therapeutic drugs. We have been working to realize these proposals.
We have been working to develop a clinical trial website that is easily accessible and searchable by patients with intractable and rare diseases and their families, in collaboration with the National Institute of Biomedical Innovation and Nutrition (NIBIO) and the research group of the "Strategic Integrated Research Program to Promote Research and Improve Medical Care to Overcome Intractable Diseases," a policy research project for intractable diseases by the Ministry of Health, Labour and Welfare of Japan. The "Intractable Disease Clinical Trial Web" has been developed in collaboration with the National Institute of Biomedical Innovation and Nutrition (NIBIO) and the Ministry of Health, Labor and Welfare (MHLW).
Intractable Disease Clinical Trials Web: https://nanbyo-chiken.nibn.go.jp/
We expect that the use of the "Intractable Disease Clinical Trials Web" by many patients will make it easier for patients to participate in clinical trials and will enable more patient-centered development than ever before, thereby contributing to the development of therapeutic drugs. The Pharmaceutical Manufacturers Association of Japan (PMAJ) will continue its activities to help solve the problems of patients with intractable and rare diseases and their families.
Intractable Disease Clinical Trials Web: https://nanbyo-chiken.nibn.go.jp/
We expect that the use of the "Intractable Disease Clinical Trials Web" by many patients will make it easier for patients to participate in clinical trials and will enable more patient-centered development than ever before, thereby contributing to the development of therapeutic drugs. The Pharmaceutical Manufacturers Association of Japan (PMAJ) will continue its activities to help solve the problems of patients with intractable and rare diseases and their families.